Navigation Links
Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
Date:10/1/2007

SEATTLE, Oct. 1 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced that two abstracts, including its late-breaking abstract for TRU-015 for rheumatoid arthritis (RA), have been accepted for presentation at the American College of Rheumatology (ACR) Annual Scientific Meeting. This meeting will be held in conjunction with the Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting Nov. 6-11, 2007, at Boston's Convention and Exhibition Center.

Poster Presentations

Thursday, Nov. 8, 2007

Poster 309: Safety and Pharmacodynamics of Repeat Administration of TRU- 015, a CD20-Directed SMIP(TM) Therapeutic, in Subjects with Rheumatoid Arthritis

Friday, Nov. 9, 2007

Poster L7: TRU-015 Improves Rheumatoid Arthritis Disease Activity in a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2 Dose Ranging Trial

Abstracts, including late-breaking, for the ACR Annual Scientific Meeting are now available online at http://www.rheumatology.org.

About Trubion

Trubion is a biopharmaceutical company creating a pipeline of product candidates to treat autoimmune disease and cancer. The company's product candidates are novel proteins known as single-chain polypeptides and are designed using its SMIP custom drug assembly technology. In less than 24 months, the company designed, developed and submitted to the FDA an Investigational New Drug (IND) application for its lead product candidate, TRU-015, which has completed a Phase IIb clinical trial for the treatment of rheumatoid arthritis. In December 2005, the company entered into a collaboration agreement with Wyeth for the development and worldwide commercialization of certain therapeutics, including TRU-015. In addition, Trubion's TRU-016 program targets CD37, an antigen present on B cells, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Subject to satisfactory completion of preclinical testing of TRU-016, the company expects to file an IND for TRU-016 in the second half of 2007. Trubion currently retains all development and commercialization rights for the TRU-016 program. For additional information visit http://www.trubion.com.

Contact:

Jim DeNike

Senior Director, Corporate Communications

Trubion Pharmaceuticals Inc.

(206) 838-0500

jdenike@trubion.com

Waggener Edstrom Healthcare

Jenny Moede

Senior Vice President

(503) 443-7000

jmoede@wagged.com

TRBN-G


'/>"/>
SOURCE Trubion
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Speaker announces business members of IT Task Force
4. Doyle announces technology tax credits for Berbee
5. Doyle announces new energy, global warming policies
6. Doyle announces $80M renewable energy strategy
7. GE announces first installation of Discovery VCT
8. UWM announces winners of RGI awards
9. Third Wave announces two senior management appointments
10. Mirus announces new method for making antibodies
11. Merge announces sofware updates, upcoming acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... WEDI, the nation’s leading authority on ... that Charles W. Stellar has been named by the WEDI Board of Directors as ... As an executive leader with more than 35 years of experience in healthcare, association ...
(Date:5/25/2016)... ... May 25, 2016 , ... Biohaven ... Administration (FDA) has granted the company’s orphan drug designation request covering BHV-4157 for ... designation granted by the FDA. , Spinocerebellar ataxia is a rare, debilitating ...
(Date:5/24/2016)... TEL AVIV, Israel , May 24, 2016   ... on providing physicians with artificial intelligence, real-time decision support tools ... selected to present at the 2016 Israeli Advanced Technology Industries ... part of Israel,s 15th National Life ... to 26th at the David Intercontinental Hotel in ...
(Date:5/24/2016)... ... 2016 , ... Media Cybernetics, global image analysis leader, announces ... reflects a results-driven revitalization for a company with a renewed focus on innovation ... crisp, refreshed logo and a new web presence. , “I believe that the ...
Breaking Biology Technology:
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
(Date:3/22/2016)... , PROVO and ... Newborn Screening Ontario (NSO), which operates the highest sample ... molecular testing, and Tute Genomics and UNIConnect, leaders in ... respectively, today announced the launch of a project to ... (NGS) testing panel. NSO has been ...
Breaking Biology News(10 mins):